Advances in DNA Repair in Cancer Therapy

1. Front Matter

   Pages i-viii

   PDF

2. Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs

   • Anderson T. Wang, Peter J. McHugh, John A. Hartley

   Pages 1-23

3. DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy?

   • Bernard Salles, Patrick Calsou, Gladys Mirey

   Pages 25-44

4. Growth Factor Receptor Signaling, DNA Damage Response, and Cancer Cell Susceptibility to Chemotherapy and Relapses

   • Moulay Alaoui-Jamali, Amine Saad, Gerald Batist

   Pages 45-74

5. The Relationship Between DNA-Repair Genes, Cellular Radiosensitivity, and the Response of Tumors and Normal Tissues to Radiotherapy

   • David Murray, Matthew Parliament

   Pages 75-128

6. Important Roles of ERCC1 in DNA Repair and Targeted Therapy

   • Jennifer J. Hu, Joseph de la Garza, Sathish K. Srinivasan, Ann Alyssa Kurian, Feng Gong

   Pages 129-142

7. The Role of BRCA1 and BRCA2 in Anticancer Drug Therapy

   • Andrew Y. Shuen, Jorge S. Reis-Filho, William D. Foulkes

   Pages 143-155

8. DNA-PK in CLL Chemotherapy

   • L. Amrein, D. Davidson, R. Aloyz, L. Panasci

   Pages 157-166

9. Poly(ADP) Ribose Polymerase at the Interface of DNA Damage Signaling and DNA Repair

   • Jana Krietsch, Michèle Rouleau, Michel Lebel, Guy Poirier, Jean-Yves Masson

   Pages 167-186

10. Cellular Protection Against the Antitumor Drug Bleomycin

    • Dindial Ramotar, Mustapha Aouida

    Pages 187-209

11. ATR as a Therapeutic Target

    • Fiona K. Middleton, Nicola J. Curtin

    Pages 211-228

12. Telomeres, Telomerase, and DNA Damage Response in Cancer Therapy

    • Raina A. Tamakawa, Helen B. Fleisig, Judy M. Y. Wong

    Pages 229-279

13. RAD51 Is a Key Protein of DNA Repair and Homologous Recombination in Humans

    • Alexander V. Mazin, Olga M. Mazina

    Pages 281-302

14. Back Matter

    Pages 303-312

    PDF

​A comprehensive review of the recent developments in DNA repair research that have potential for translational applications. The book explains in detail the various biological mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK. The book captures-for both cancer researchers and oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.​

• DNA damage
• DNA-PK
• ERCC1
• chemotherapeutic drugs
• telomeres

• Jewish General Hospital, Montreal, Canada

  Lawrence Panasci

• , Department of Oncology, McGill University, Montreal, Canada

  Raquel Aloyz

• McGill University, Department of Medicine and Oncology, Faculty of Medicine, Montreal, Canada

  Moulay Alaoui-Jamali

Policies and ethics